Clinical Psychopharmacology: An Update
()
About this ebook
This book provides practical information on how to use various psychotropic drugs in clinical practice, focusing on their mechanisms of action on receptors and enzymes in the brain. Divided into 11 chapters, it covers all main drug classes, with a dedicated chapter each on special populations and upcoming drugs. All the drugs discussed are presented in the same design format in order to facilitate rapid access to information. Specifically, each drug is individually divided into sections - its history and introduction, classification, pharmacological action, doses, drug interactions, indications, side effects and special populations. Only the essential facts about each drug have been included, so as to make the content concise and to avoid dilution of important information. To aid with review, key points are summarized at the end of each chapter.
Related to Clinical Psychopharmacology
Related ebooks
Psychosomatic Energetics Textbook Rating: 0 out of 5 stars0 ratingsMind Boosters: A Guide to Natural Supplements That Enhance Your Mind, Memory, and Mood Rating: 5 out of 5 stars5/5Nutrient-Based Psychiatry: A Nutritional Prescription for ADHD Rating: 0 out of 5 stars0 ratingsPsychopharmacology for Medical Students Rating: 5 out of 5 stars5/5Prescribing Psychotropics: From Drug Interactions to Pharmacogenetics Rating: 5 out of 5 stars5/5The Maudsley Prescribing Guidelines in Psychiatry Rating: 4 out of 5 stars4/5The Bitterest Pills: The Troubling Story of Antipsychotic Drugs Rating: 0 out of 5 stars0 ratingsGet Smart About Meth and Other Stimulants Rating: 5 out of 5 stars5/5The Natural Medicine Guide to Depression Rating: 5 out of 5 stars5/5Alternative Treatments of PTSD: Safe, Effective and Affordable Approaches and How to Use Them Rating: 5 out of 5 stars5/5Psychopharmacology: A Clinician's Guide for the Effective use of Psychotropic Medications Rating: 0 out of 5 stars0 ratingsClinical Management of Insomnia, 3rd ed Rating: 0 out of 5 stars0 ratingsEmergencies in Neurology: Volume I Rating: 0 out of 5 stars0 ratingsAlternative Treatments of Schizophrenia: Safe, Effective and Affordable Approaches and How to Use Them Rating: 5 out of 5 stars5/5Analytical Hypnotherapy: A Beginner's 3-Step Quick Start Guide, with an FAQ Rating: 0 out of 5 stars0 ratingsAnalytical Hypnotherapy: A Beginner's 3-Step Quick Start Guide, with an FAQ Rating: 0 out of 5 stars0 ratingsPharmacotherapy of Child and Adolescent Psychiatric Disorders Rating: 0 out of 5 stars0 ratingsPsychopharmacology in Family Practice Rating: 0 out of 5 stars0 ratingsPsychiatry Practice Boosters, Third Edition Rating: 0 out of 5 stars0 ratingsCoping with Depression: A Guide to What Works for Patients, Carers, and Professionals Rating: 0 out of 5 stars0 ratingsThe Massachusetts General Hospital Guide to Depression: New Treatment Insights and Options Rating: 0 out of 5 stars0 ratingsAlternative Treatments of Bipolar Disorder: Safe, Effective and Affordable Approaches and How to Use Them Rating: 4 out of 5 stars4/5Psychopharmacology in Oncology and Palliative Care: A Practical Manual Rating: 0 out of 5 stars0 ratingsHandbook of Methadone Prescribing and Buprenorphine Therapy Rating: 0 out of 5 stars0 ratingsAlternative Treatments of Depression: Safe, Effective and Affordable Approaches and How to Use Them Rating: 5 out of 5 stars5/5Pharmacological Basis of Acute Care Rating: 0 out of 5 stars0 ratingsMind/Body Therapy: Visual, Auditory, Kinesthetic-NLP Rating: 0 out of 5 stars0 ratingsHow to Make Your Own Nootropics Rating: 4 out of 5 stars4/5Advanced Pharmacology Rating: 0 out of 5 stars0 ratings
Medical For You
The Vagina Bible: The Vulva and the Vagina: Separating the Myth from the Medicine Rating: 5 out of 5 stars5/5Brain on Fire: My Month of Madness Rating: 4 out of 5 stars4/5What Happened to You?: Conversations on Trauma, Resilience, and Healing Rating: 4 out of 5 stars4/5Mediterranean Diet Meal Prep Cookbook: Easy And Healthy Recipes You Can Meal Prep For The Week Rating: 5 out of 5 stars5/5The Emperor of All Maladies: A Biography of Cancer Rating: 5 out of 5 stars5/5The Diabetes Code: Prevent and Reverse Type 2 Diabetes Naturally Rating: 4 out of 5 stars4/5Mating in Captivity: Unlocking Erotic Intelligence Rating: 4 out of 5 stars4/5Adult ADHD: How to Succeed as a Hunter in a Farmer's World Rating: 4 out of 5 stars4/5Gut: The Inside Story of Our Body's Most Underrated Organ (Revised Edition) Rating: 4 out of 5 stars4/5Peptide Protocols: Volume One Rating: 4 out of 5 stars4/5"Cause Unknown": The Epidemic of Sudden Deaths in 2021 & 2022 Rating: 5 out of 5 stars5/5The People's Hospital: Hope and Peril in American Medicine Rating: 4 out of 5 stars4/5The Song of the Cell: An Exploration of Medicine and the New Human Rating: 4 out of 5 stars4/5Women With Attention Deficit Disorder: Embrace Your Differences and Transform Your Life Rating: 5 out of 5 stars5/5Herbal Healing for Women Rating: 4 out of 5 stars4/5Living Daily With Adult ADD or ADHD: 365 Tips o the Day Rating: 5 out of 5 stars5/5WomanCode: Perfect Your Cycle, Amplify Your Fertility, Supercharge Your Sex Drive, and Become a Power Source Rating: 4 out of 5 stars4/5As Nature Made Him: The Boy Who Was Raised as a Girl Rating: 4 out of 5 stars4/5ATOMIC HABITS:: How to Disagree With Your Brain so You Can Break Bad Habits and End Negative Thinking Rating: 5 out of 5 stars5/5Holistic Herbal: A Safe and Practical Guide to Making and Using Herbal Remedies Rating: 4 out of 5 stars4/5Working Stiff: Two Years, 262 Bodies, and the Making of a Medical Examiner Rating: 4 out of 5 stars4/5The 40 Day Dopamine Fast Rating: 4 out of 5 stars4/5Tight Hip Twisted Core: The Key To Unresolved Pain Rating: 4 out of 5 stars4/5
Reviews for Clinical Psychopharmacology
0 ratings0 reviews
Book preview
Clinical Psychopharmacology - Prakash B. Behere
© Springer Nature Singapore Pte Ltd. 2019
Prakash B. Behere, Anweshak Das and Aniruddh P. BehereClinical Psychopharmacologyhttps://doi.org/10.1007/978-981-13-2092-7_1
1. Antidepressants
Prakash B. Behere¹ , Anweshak Das² and Aniruddh P. Behere³
(1)
Department of Psychiatry, D Y Patil Medical College & D. Y. Patil Education Society (Deemed University), Kolhapur, Maharashtra, India
(2)
Consultant Psychiatrist, Psychiatric Clinic, Guwahati, Assam, India
(3)
Pediatric Behavior Health , Helen Devos Childrens’s Hospital, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA
1.1 Tricyclic and Tetracyclic Antidepressants
Class of Drug
Tricyclic and Tetracyclic antidepressants.
History and Introduction
Tricyclics were the first drugs introduced for the treatment of depression. Like lithium and chlorpromazine the invention was serendipitous. In 1957, Ronald Kuhn, a Swiss psychiatrist, observed the effects of imipramine as antidepressant.
Chemistry
These compounds are characterized mainly on the basis of their structures. The tricyclics have a three-ring central structure, and tetracyclics have a four-ring central structure. The tertiary amine tricyclics such as Imipramine and Amytriptiline have two methyl groups at the end of side chain. These compounds can be demethylated to secondary amines such as desipramine and nortriptyline.
Pharmacokinetics
Absorption of Tricyclics and Tetracyclics occur in the small intestine and is reasonably complete and rapid. Peak levels are reached after 2–8 h of ingestion, except for the drugs Protryptiline and Maprotiline, which reach their peak level after 8 h. These compounds are basic lipophilic amines. As a result, they are concentrated in a variety of body tissues such as cardiac tissue and cause cardiac side effects. These compounds are highly lipid soluble and are 90% bound to serum proteins. After absorption, they first pass metabolism in the liver. Clearance is principally through metabolism in the liver. Renal clearance accounts for a very small amount of drug. Elimination half-lives are approximately more than 24 h with an exception, which has half-life of 5–10 h. Most of TCAs follow the linear kinetics.
Pharmacodynamics
Reuptake blockade—These drugs block the reuptake of serotonin and norepinephrine at presynaptic sites and increase the amount of these amines. The tertiary amines have a higher affinity for norepinephrine, and secondary amines have a higher affinity for serotonin. TCAs also increase dopamine transmission in frontal cortex.
Receptor sensitivity changes—The Tricyclic agents sensitize or upregulate postsynaptic 5-HT1A receptors. These changes in sensitivity of the presynaptic and postsynaptic receptors occur over a period of 2 weeks, and the onset of these changes is more consistent with the timing of antidepressant response than the initial uptake blockade.
Secondary effects—The Tricyclic and Tetracyclic compounds have effects on a variety of receptors. In particular, these drugs act on muscarinic receptors producing anticholinergic effects. They block Histamine 1 receptors producing sedation. They also block alpha 1 and alpha 2 receptors. They have effects on fast sodium channels which explain their cardiac side effects.
Doses [1, 2]
Augmenting Agents
Gabapentin for neuropathic pain along with amitriptyline. Fluvoxamine can be added along with clomipramine for treatment of resistant OCD. Atypical antipsychotics can also be added for OCD Thyroid hormones, and lithium can be added for resistant depression as a form of psychotherapy.
Drug Interactions
Sudden increases in catecholamine levels if used with MAOIs.
Concomitant use of quinidine can cause a heart block.
Drugs that inhibit CYP 2D6 like Fluoxetine and Paroxetine can increase the levels of amines.
Drugs which induce CYP enzymes like Carbamazepine and barbiturates can decrease the levels of these drugs.
Use of TCAs with sympathomimetics may increase sympathetic activity.
Haloperidol may increase levels of TCAs.
TCAs with anticholinergics can cause paralytic ileus and hypothermia.
Indications
Depressive disorders—It has been suggested that TCAs are more effective than SSRIs in severe depressive episodes with melancholic features. For depressive disorders with predominant anxiety symptoms drugs like Doxepin, Amoxapine, and Maprotiline are more effective. Patients of depression with atypical features are more effective. These compounds are not so useful in psychotic depression. They are also useful in insomnia.
Panic disorders, migraine, Enuresis, Cataplexy—Imipramine.
Obsessive compulsive disorders, Cataplexy syndrome—Clomipramine.
Neuropathic pain, Headache, Fibromyalgia—Amytriptiline.
ADHD—Desipramine.
Side Effects
Central nervous system side effects—The central anticholinergic effects can produce seizures and delirium. Both of these side effects are dose dependent and become more likely to occur at elevated blood levels. Incidence of delirium increases if blood levels raise more than 300 ng/mL and seizures after levels greater than 450 ng/mL, especially with Amytriptiline.
The tricyclics can cause fine rapid tremors which is also a dose-related side effect. Because the 7-Hydroxymetabolite of Amoxapine has Neuroleptic effects, it can cause Neuroleptic Malignant Syndrome.
Autonomic side effects—Anticholinergic side effects like dry mouth, constipation, blurring of vision, urinary hesitancy, delirium, and ocular crisis in patients with narrow angle glaucoma. Desipramine has the least anticholinergic side effects.
Cardiovascular effects—Orthostatic hypotension is the most common side effect. Elderly people are more prone to falls. Tachycardia occurs with all the tricyclics.
Cardiac conduction defects—The Tricyclic antidepressants have type 1 antiarrhythmic effects. In patients with conduction delay, it can cause heart block. It causes QT prolongation.
Hepatic effects—liver enzyme AST levels can be raised.
Other adverse effects—sexual dysfunction, allergic skin rashes.
Teratogenicity—Isolated reports of morphogenesis reported, neonatal drug withdrawal can occur which is characterized by tachypnea, cyanosis, irritability, and poor suckling reflex.
Weight gain: Commonly causes weight gain. If a patient has gained 5% of initial weight, consider evaluating for diabetes or dyslipidemia.
Rarely can cause paralytic ileus which can be life threatening.
Overdose
Death most commonly occurs as a result of cardiac toxicity. It causes seizures, cardiac dysrhythmias, hypotension, and coma.
Special Populations
Precautions
Should not be used with MAO inhibitors.
Should be used in patients who are on calcium channel blockers or beta blockers.
Should be used with caution in patients who have hypokalemia and hypomagnesemia.
Should be avoided in patients having history of seizures, glaucoma.
To decrease withdrawal symptoms should be tapered down slowly.
1.2 Specific Serotonin Reuptake Inhibitors [6]
1.2.1 Fluoxetine
Class of Drug
Selective Serotonin Reuptake Inhibitor.
History and Introduction
Fluoxetine was the first SSRI to be introduced in 1987.
Pharmacokinetics
It is well absorbed orally with 70–90% bioavailability. Food may delay absorption for 1–2 h. It is 95% bound to serum proteins. Its active metabolite norfluoxetine has a half-life of 2 weeks. Parent drug has a half-life of 2–3 days. It inhibits CYP 450 2D6 and CYP 450 3A4.
Pharmacodynamics
Therapeutic activity is due to specific 5-HT reuptake inhibition at the presynaptic serotonergic nerve terminal. It desensitizes serotonin receptors, especially serotonin 1A receptors. Fluoxetine has partial antagonist action at 5HT2C receptors which could increase norepinephrine and dopamine neurotransmitter.
Doses
Onset of Action
Onset of therapeutic action is not immediate. It may take 2–4 weeks to show its action.
Augmenting Combination
Mood stabilizers or atypical antipsychotics for bipolar depression, psychotic depression, or treatment-resistant depression.
Modafinil for fatigue, sleepiness, and lack of concentration.
Fluoxetine has been specially studied in combination with olanzapine, with excellent results for bipolar depression, treatment-resistant unipolar depression, and psychotic depression.
Drug Interactions
Increases the levels of TCAs.
Can cause Serotonin syndrome if combined with Mono amine Oxidase Inhibitors (MAOIs).
Can cause Serotonin syndrome if combined with dopamine antagonists.
By inhibition of CYP, it can increase serum concentration of many drugs, e.g., beta blockers, thioridazine, alprazolam, buspirone, and pimozide.
Possible increased risk of bleeding especially when combined with anticoagulants like warfarin and NSAIDS.
Indications
Major depressive disorder
Bipolar depression
Dysthymia
Seasonal affective disorder
Obsessive compulsive disorder
Bulimia Nervosa
Panic disorder
Premenstrual dysphoric disorder
Trichotilomania
Post-traumatic stress disorder
Social anxiety disorder
Body dysmorphic disorder
Substance dependence
Smoking cessation
Premature ejaculation
Chronic fatigue syndrome
Fibromyalgia
Raynaud’s phenomenon
Post stroke depression
Postmenopausal hot flashes
Side Effects
Fluoxetine unique 5HT2C antagonist properties could contribute to agitation and anxiety.
Sexual dysfunction: delayed ejaculation in men and decreased sexual desire in women.
Gastrointestinal dysfunction: loss of appetite, nausea, diarrhea, constipation, dry mouth.
CNS: Insomnia, agitation, tremors, headache, dizziness, rarely seizures.
Autonomic: sweating.
Rare induction of mania.
Overdose
May be lethal in overdoses.
Precautions and Contraindications
Use in seizure disorder may decrease seizure threshold.
In bipolar depression, it should be used along with mood stabilizer.
Should not be given if patient is taking MAOIs, thioridazine, or pimozide or has any proven allergy to Fluoxetine.
Monitor patients for suicidal ideation, especially in children and adolescents.
Special Populations
1.2.2 Sertraline
Class of Drug
Selective Serotonin Reuptake inhibitor.
History and Introduction
Sertraline was the second member of SSRI to be introduced in 1992.
Pharmacokinetics
It is well absorbed orally. When given with food, plasma concentration reaches maximum value in 5–6 h, as compared to when it is given without food (which is 8 h). It is 98% bound to serum proteins. Half-life of Sertraline is 26 h and its metabolite’s (N-desmethylsertraline) half-life is 62–104 h. It inhibits CYP 450 2D6 and CYP 450 3A4.
Pharmacodynamics
Therapeutic activity is due to specific 5-HT reuptake inhibition at the presynaptic serotonergic nerve terminal. It also has some ability to block dopamine reuptake pumps. It desensitizes serotonin receptors, especially serotonin 1A receptors.
Onset of Action
Onset of therapeutic action is not immediate. It may take 2–4 weeks to show its action.
Augmenting Combination
Mood stabilizers or atypical antipsychotics for bipolar depression, psychotic depression, or treatment-resistant depression.
Modafinil for fatigue, sleepiness, and lack of concentration.
Doses
Drug Interactions
Increases the levels of TCAs.
Can cause Serotonin Syndrome if combined with Monoamine Oxidase Inhibitors (MAOIs).
By inhibition of CYP, it can increase serum concentration of many drugs, e.g., beta blockers, thioridazine, alprazolam, and buspirone.
Indications
Atypical depression (may be a first line of choice)
Major depressive disorder
Dysthymia
Chronic depression
Obsessive compulsive disorder
Panic disorder
Premenstrual dysphoric disorder
Post-traumatic stress disorder
Social anxiety disorder
Premature ejaculation
Side Effects
Increasing serotonin can cause diminished dopamine release, and might cause emotional flattening, cognitive slowing, and apathy in some patients.
Sexual dysfunction: delayed ejaculation in men and decreased sexual desire in women.
Gastrointestinal dysfunction: loss of appetite, nausea, diarrhea, constipation, dry mouth.
CNS: insomnia, agitation, tremors, tics, headache, dizziness, rarely seizures.
Autonomic: sweating, orthostatic hypotension.
Rarely induction of mania.
Hyponatremia and hypotension mostly in elderly (rarely).
Overdose
Causes vomiting, sedation, heart rhythm disturbances, dilated pupils, and agitation.
Precautions and Contraindications
Use in seizure disorder may decrease seizure threshold, add/initiate other antidepressant with caution for up to 2 weeks of discontinuation of Sertraline. In bipolar depression, it should be used along with a mood stabilizer. The drug should not be administered if patient is taking MAOIs, thioridazine, or pimozide, or if patient has any proven allergy to Sertraline.
Special Populations
1.2.3 Fluvoxamine
Class of Drug
Selective Serotonin Reuptake inhibitor.
History and Introduction
Fluvoxamine was initially introduced in Switzerland in 1983.
Pharmacokinetics
Oral bioavailability is about 50%. Its absorption is not affected by food. Plasma concentration reaches maximum in 3–8 h. The primary site of metabolism is liver. It follows nonlinear pharmacokinetics. The half-life of the drug is 9–28 h.
Pharmacodynamics
Therapeutic activity is due to specific 5-HT reuptake inhibition at the presynaptic serotonergic nerve terminal. It also has antagonist properties at sigma 1 receptors.
Onset of Action
Some patients may experience relief from insomnia and anxiety, early after initiation of treatment. Onset of therapeutic action is not immediate. It may take 2–4 weeks to show its action.
Augmenting Combination
For OCD clomipramine can be added on.
Mood stabilizers or atypical antipsychotics for bipolar depression, psychotic depression, treatment-resistant depression, or treatment-resistant anxiety disorders.
For anxiety disorders gabapentin may also be added.
Modafinil for fatigue, sleepiness, and lack of concentration.